share_log

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 43% Over the Past Week

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 43% Over the Past Week

Ventyx Biosciences, Inc.(纳斯达克:VTYX)的主要机构投资者们一定很高兴,因为该股票持续给人留下深刻印象,上周上涨了43%。
Simply Wall St ·  2024/11/27 04:12

Key Insights

主要见解

  • Given the large stake in the stock by institutions, Ventyx Biosciences' stock price might be vulnerable to their trading decisions
  • 53% of the business is held by the top 9 shareholders
  • Insiders have bought recently
  • 考虑到机构在该股票中持有大部分股份,Ventyx Biosciences的股价可能会受到他们的交易决策的影响。
  • 业务的53%由前9大股东持有。
  • 内部人士最近购买了股票。

To get a sense of who is truly in control of Ventyx Biosciences, Inc. (NASDAQ:VTYX), it is important to understand the ownership structure of the business. We can see that institutions own the lion's share in the company with 59% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

要了解真正控制Ventyx Biosciences, Inc. (NASDAQ:VTYX)的人是谁,重要的是了解公司的所有权结构。我们可以看到,机构拥有该公司59%的股份。换句话说,该团体将从对该公司的投资中获益最多(或损失最多)。

And last week, institutional investors ended up benefitting the most after the company hit US$146m in market cap. One-year return to shareholders is currently 10% and last week's gain was the icing on the cake.

上周,机构投资者受益最多,因为公司市值达到了14600万美元。股东的一年回报率目前为10%,上周的收益是锦上添花。

Let's delve deeper into each type of owner of Ventyx Biosciences, beginning with the chart below.

让我们深入研究每种Ventyx Biosciences所有者的类型,从下面的图表开始。

big
NasdaqGS:VTYX Ownership Breakdown November 27th 2024
纳斯达克指数:VTYX 2024年11月27日的所有权拆分

What Does The Institutional Ownership Tell Us About Ventyx Biosciences?

关于Ventyx Biosciences的机构持股告诉我们什么?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

机构通常在向自己的投资者报告时会针对一个基准进行衡量,因此一旦某只股票被纳入主要指数,他们通常会更加热衷于该股票。我们预计大多数公司都会有一些机构在登记簿上,尤其是那些正在增长的公司。

As you can see, institutional investors have a fair amount of stake in Ventyx Biosciences. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Ventyx Biosciences' earnings history below. Of course, the future is what really matters.

正如您所见,机构投资者在Ventyx Biosciences中持有相当大比例的股份。这意味着为这些机构工作的分析师已经研究了该股票并且他们喜欢它。但就像其他人一样,他们也可能错。如果多家机构同时改变对一只股票的看法,那么股价可能会快速下跌。因此,查看Ventyx Biosciences的历史收入数据是值得的。当然,未来才是真正重要的。

big
NasdaqGS:VTYX Earnings and Revenue Growth November 27th 2024
纳斯达克GS:VTYX盈利和营收增长2024年11月27日

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It would appear that 16% of Ventyx Biosciences shares are controlled by hedge funds. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. The company's largest shareholder is New Science Ventures, LLC, with ownership of 10%. In comparison, the second and third largest shareholders hold about 9.5% and 6.9% of the stock. Furthermore, CEO Raju Mohan is the owner of 2.4% of the company's shares.

投资者应注意,机构实际上拥有超过公司一半的股份,因此它们可以集体行使重要权力。看来Ventyx Biosciences股份的16%受到对冲基金的控制。这引起了我的注意,因为对冲基金有时会试图影响管理层,或提出改变,从而为股东创造短期价值。该公司最大的股东是New Science Ventures,LLC,持有10%的股份。相比之下,第二和第三大股东持有约9.5%和6.9%的股份。此外,首席执行官Raju Mohan拥有公司股份的2.4%。

We did some more digging and found that 9 of the top shareholders account for roughly 53% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

我们进行了更深入的调查,发现前9大股东大约占注册股份的53%,这意味着除了较大的股东,还有一些较小的股东,从而在一定程度上平衡彼此的利益。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

研究机构所有权是衡量和过滤股票预期表现的好方法。通过研究分析师的情绪也可以实现同样的目的。由于有相当数量的分析师涵盖这支股票,因此了解他们对未来的整体看法可能会有所帮助。

Insider Ownership Of Ventyx Biosciences

Ventyx生物科学的内部所有权

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

公司内部人员的定义可能是主观的,并在不同的司法管辖区之间有所不同。我们的数据反映了个人内部人员,至少包括董事会成员。管理层最终向董事会负责。然而,经理们成为执行董事会成员并不罕见,尤其是如果他们是创始人或首席执行官。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多数人认为内部所有权是积极的,因为它可以表示董事会与其他股东的利益相一致。但是,在某些场合下,这个团体的权力过于集中。

We can see that insiders own shares in Ventyx Biosciences, Inc.. It has a market capitalization of just US$146m, and insiders have US$4.7m worth of shares, in their own names. It is good to see some investment by insiders, but we usually like to see higher insider holdings. It might be worth checking if those insiders have been buying.

我们可以看到,在Ventyx Biosciences,Inc.,内部持股。其市值仅为14600万美元,内部人士拥有470万美元的股份,以自己的名义持有。看到内部人员进行一些投资是好事,但我们通常希望看到更高的内部持股。也许值得检查这些内部人员是否一直在买入。

General Public Ownership

一般大众所有权

With a 12% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Ventyx Biosciences. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

在Ventyx Biosciences拥有12%的股权,主要由个人投资者构成的普通大众对其具有一定的影响力。尽管这种持股规模相当可观,但如果决定与其他大股东不一致,可能还不足以改变公司政策。

Private Equity Ownership

股权投资公司持有8.8%的股份,有能力参与塑造以价值创造为重点的公司策略。一些投资者可能会因此而受到鼓舞,因为股权投资公司有时可以鼓励市场看到公司的价值,从而采取有益的策略。另外,那些持有者可能在将其上市后退出投资。

With an ownership of 10%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

拥有10%股权的股权投资公司有机会在塑造企业价值创造为重点的战略中发挥作用。有些人可能喜欢这种情况,因为股权投资有时是活跃分子,追究管理层的责任。但有时,股权投资却在出售股权,将公司推向公开市场。

Next Steps:

下一步:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For example, we've discovered 4 warning signs for Ventyx Biosciences (1 shouldn't be ignored!) that you should be aware of before investing here.

尽管考虑公司的不同股东群体是值得的,但还有其他更重要的因素。 例如,我们发现了Ventyx Biosciences的4个警示信号(1个不容忽视!),在您投资这里之前,您应该意识到这些。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

最终,未来最重要。您可以在这份关于该公司分析师预测的免费报告中获取有关信息。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发